Deflazacort Use in Duchenne Muscular Dystrophy: An 8-Year Follow-Up

Brooke, 1996, A randomized trial of deflazacort and prednisone in Duchenne muscular dystrophy: efficacy and toxicity, Neurology, 46, A476

Mesa, 1991, Steroids in Duchenne muscular dystrophy: deflazacort trial, Neuromuscul Disord, 1, 261, 10.1016/0960-8966(91)90099-E

Fenichel, 1991, A comparison of daily and alternate-day prednisone therapy in the treatment of Duchenne muscular dystrophy, Arch Neurol, 48, 575, 10.1001/archneur.1991.00530180027012

Fenichel, 1991, Long-term benefit from prednisone therapy in Duchenne muscular dystrophy, Neurology, 41, 1874, 10.1212/WNL.41.12.1874

Sansome, 1993, Steroids in Duchenne muscular dystrophy: pilot study of a new low-dosage schedule, Neuromuscul Disord, 3, 567, 10.1016/0960-8966(93)90117-3

Griggs, 1993, Duchenne dystrophy: Randomized, controlled trial of prednisone (18 months) and azathioprine (12 months), Neurology, 43, 520, 10.1212/WNL.43.3_Part_1.520

Reitter, 1995, Deflazacort vs. prednisone in Duchenne muscular dystrophy: trends of an ongoing study, Brain Dev, 17, 39, 10.1016/0387-7604(95)00015-1

Angelini, 1994, Deflazacort in Duchenne dystrophy: study of long-term effect, Muscle Nerve, 17, 386, 10.1002/mus.880170405

Carter, 2000, Preserving function in Duchenne dystrophy with long-term pulse prednisone therapy, Am J Phys Med Rehabil, 79, 455, 10.1097/00002060-200009000-00009

Biggar, 2001, Deflazacort treatment of Duchenne muscular dystrophy, J Pediatr, 138, 45, 10.1067/mpd.2001.109601

Bonifati, 2000, A multicenter, double-blind, randomized trial of deflazacort versus prednisone in Duchenne muscular dystrophy, Muscle Nerve, 23, 1344, 10.1002/1097-4598(200009)23:9<1344::AID-MUS4>3.0.CO;2-F

Schara, 2001, Long-term steroid therapy in Duchenne muscular dystrophy: positive results versus side effects, J Clin Neuromuscul Dis, 2, 179, 10.1097/00131402-200106000-00002

Wong, 2002, Corticosteroids in Duchenne muscular dystrophy: a reappraisal, J Child Neurol, 17, 183, 10.1177/088307380201700306

Dubowitz, 2002, Remission of clinical signs in early Duchenne muscular dystrophy on intermittent low-dosage prednisolone therapy, Eur J Paediatr Neurol, 6, 153, 10.1053/ejpn.2002.0583

Connolly, 2002, High dose weekly oral prednisone improves strength in boys with Duchenne muscular dystrophy, Neuromuscul Disord, 12, 917, 10.1016/S0960-8966(02)00180-3

Biggar, 2004, Deflazacort in Duchenne muscular dystrophy: a comparison of two different protocols, Neuromuscul Disord, 14, 476, 10.1016/j.nmd.2004.05.001

Dubowitz, 2000, 75th European Neuromuscular Centre International Workshop: 2nd workshop on the treatment of muscular dystrophy, 10-12 December, 1999, Naarden, The Netherlands, Neuromuscul Disord, 10, 313, 10.1016/S0960-8966(00)00126-7

Biggar, 2006, Long-term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade, Neuromuscul Disord, 16, 249, 10.1016/j.nmd.2006.01.010

Markham, 2005, Steroid therapy and cardiac function in Duchenne muscular dystrophy, Pediatr Cardiol, 26, 768, 10.1007/s00246-005-0909-4

Jefferies, 2005, Genetic predictors and remodeling of dilated cardiomyopathy in muscular dystrophy, Circulation, 112, 2799, 10.1161/CIRCULATIONAHA.104.528281

Alman, 2004, Steroid treatment and the development of scoliosis in males with Duchenne muscular dystrophy, J Bone Joint Surg Am, 86-A, 519, 10.2106/00004623-200403000-00009

Polgar, 1971, Standard values, 102

Muntoni, 2006, Muscular Dystrophy Campaign Funded Workshop on Management of Scoliosis in Duchenne Muscular Dystrophy, 24 January 2005, London, UK, Neuromuscul Disord, 16, 210, 10.1016/j.nmd.2006.01.004

Balaban, 2005, Corticosteroid treatment and functional improvement in Duchenne muscular dystrophy: long-term effect, Am J Phys Med Rehabil, 84, 843, 10.1097/01.phm.0000184156.98671.d0

Silversides, 2003, Effects of deflazacort on left ventricular function in patients with Duchenne muscular dystrophy, Am J Cardiol, 91, 769, 10.1016/S0002-9149(02)03429-X

McDonald, 1995, Profiles of neuromuscular diseases: Duchenne muscular dystrophy, Am J Phys Med Rehabil, 74, S70, 10.1097/00002060-199509001-00003

Hawker, 2005, Alendronate in the treatment of low bone mass in steroid-treated boys with Duchenne’s muscular dystrophy, Arch Phys Med Rehabil, 86, 284, 10.1016/j.apmr.2004.04.021

Rapaport, 1991, Short stature in Duchenne muscular dystrophy, Growth Regul, 1, 11

Larson, 2000, Bone mineral density and fractures in boys with Duchenne muscular dystrophy, J Pediatr Orthop, 20, 71, 10.1097/00004694-200001000-00016

Bianchi, 2003, Bone mineral density and bone metabolism in Duchenne muscular dystrophy, Osteoporos Int, 14, 761, 10.1007/s00198-003-1443-y

Vestergaard, 2001, Fracture risk in patients with muscular dystrophy and spinal muscular atrophy, J Rehabil Med, 33, 150, 10.1080/165019701750300609

McDonald, 2002, Fracture prevalence in Duchenne muscular dystrophy, Dev Med Child Neurol, 44, 695, 10.1111/j.1469-8749.2002.tb00272.x

Talim, 2002, Vertebral compression in Duchenne muscular dystrophy following deflazacort, Neuromuscul Disord, 12, 294, 10.1016/S0960-8966(01)00307-8